drugset / Trial / NCT06227975

A Study to Evaluate the Absorption, Metabolism, and Excretion of Orally Administered [14C]-BMS-986368 in Healthy Male Participants

NCT06227975

Phase 1 Completed 8 enrolled Celgene Corporation
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the pharmacokinetics (PK), metabolites, route of elimination, and mass balance of BMS-986368 in healthy male participants.

Timeline

Start
2024-02-02
Primary completion
2024-04-03
Completion
2024-04-03

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986368 Unknown

Indications

No indication recorded.